AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03942211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
Trial: NCT01211951
Drug: KCT-0809
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01211951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05514340
Drug: Sovateltide along with standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
Trial: NCT04380233
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Trial: NCT04541550
Drug: AMP-001 Medium Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
Trial: NCT06298071
Drug: SIBP-R002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Trial: NCT06298071
Drug: SIBP-R002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Trial: NCT06298071
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination drugs: Methotrexate, dose15 mg, oral.
Trial: NCT06299709
Drug: VNZ/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC granules for oral administration.
Trial: NCT06201507
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Trial: NCT05050604
Drug: Placebo of Choline Alfoscerate 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
Trial: NCT06474052
Drug: Gelofusine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
Trial: NCT06208033
Drug: SMET12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Trial: NCT06208033
Drug: SMET12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Trial: NCT06208033
Drug: SMET12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Trial: NCT05184218
Drug: IGM-6268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT05184218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT05784350
Drug: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.
Trial: NCT06431490
Drug: TQB2102 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Trial: NCT05712616
Drug: Lacto-N-Hexaose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo look alike drug
Trial: NCT02389933
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
Trial: NCT05645315
Drug: TQB2618 injection and TQB2450 injection
RxNorm normalized name: INFLAMMATION AND INFECTION DETECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
Trial: NCT05937191
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid Treatment
Trial: NCT04875585
Drug: Adjuvant Treatment Phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with 15 cycles of Pembrolizumab
Trial: NCT05295043
Drug: (CDK)4/6 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
Trial: NCT04967950
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate
Trial: NCT05044962
Drug: NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
Trial: NCT04476277
Drug: Biotin label
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
Trial: NCT05078827
Drug: Test Product (A): Fluorouracil Cream, 5% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Trial: NCT05078827
Drug: Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Trial: NCT05078827
Drug: Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Trial: NCT04834427
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Trial: NCT05421195
Drug: corticosteroids therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids
Trial: NCT04387617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
Trial: NCT05318755
Drug: GAHT for transgender women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Trial: NCT04937738
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Trial: NCT04937738
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m²d1 i.v. every 2 weeks
Trial: NCT04937738
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² two times per day (BID), d1-14
Trial: NCT04926701
Drug: ETD001 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of inhaled ETD001
Trial: NCT04926701
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of inhaled placebo
Trial: NCT04926701
Drug: ETD001 multiple twice daily doses
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascending doses of inhaled ETD001 administered twice daily
Trial: NCT04926701
Drug: Placebo multiple twice daily doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of inhaled placebo administered twice daily
Trial: NCT04926701
Drug: ETD001 multiple once daily doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of inhaled ETD001 administered once daily
Trial: NCT04926701
Drug: Placebo multiple once daily doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of inhaled placebo administered once daily
Trial: NCT04801368
Drug: Randomization of two local anesthetics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
Trial: NCT04671407
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic Saline 3% and 0.9%
Trial: NCT05341856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
Trial: NCT05077501
Drug: ACD856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
Trial: NCT05077501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT06495047
Drug: Long-acting bronchodilator therapy (LABD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting inhaler therapy
Trial: NCT06495047
Drug: Short-acting bronchodilator therapy (SABD)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting inhaler therapy
Trial: NCT06106152
Drug: WTX212A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The WTX212A infusion is given every 21 days
Trial: NCT06106152
Drug: PD -1/PD-L1 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PD -1/PD-L1 monoclonal antibody is given every 21 days
Trial: NCT05156086
Drug: COVID-19 vaccine, booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional dose of COVID-19 vaccine (booster shot)
Trial: NCT05548231
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05548231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04665206
Drug: VT3989
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 50, 100,150 or 200 mg capsules for oral administration.
Trial: NCT06476704
Drug: Administration of L-TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
Trial: NCT05520944
Drug: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
Trial: NCT05955326
Drug: Sovateltide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
Trial: NCT05562466
Drug: QMF149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 75/40 μg o.d via Breezhaler
Trial: NCT04286295
Drug: Nicoderm C-Q Transdermal Product
RxNorm normalized name: Nicoderm C-Q Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
Trial: NCT04286295
Drug: Nicorette Lozenge Product
RxNorm normalized name: Nicorette Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
Trial: NCT06679387
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A once daily matched tablet of placebo for 12 weeks
Trial: NCT04836182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Trial: NCT04792580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
Trial: NCT02190786
Drug: KUX-1151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06039826
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06267183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ： single-dose
Trial: NCT05647291
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/1ml methylprednisolone, two sessions once a week
Trial: NCT04610580
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 will be administered orally.
Trial: NCT05692934
Drug: HR20031 FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
Trial: NCT05692934
Drug: HR20031 FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
Trial: NCT05692934
Drug: HR20031 FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
Trial: NCT05692934
Drug: HR20031 FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
Trial: NCT04386980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent in normal saline
Trial: NCT06394492
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose 2
Trial: NCT06622486
Drug: EGL-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT05908695
Drug: GV-971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO
Trial: NCT05908695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO
Trial: NCT06458257
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT05741502
Drug: Antipsychotics,Other (non-Clozapine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will assess monitor inflammatory/immune marker lab
Trial: NCT05132439
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to active study drug
Trial: NCT06141590
Drug: administration of UIC202205, UIC202206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference
Trial: NCT05455788
Drug: Aminoglycoside
RxNorm normalized name: Aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of sewing ring of prosthetic valve with aminoglycoside
Trial: NCT04931862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial cerebrospinal fluid (aCSF)
Trial: NCT05104892
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT05065541
Drug: [18F]T-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06406010
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered in a pericapsular nerve group (PENG) block
Trial: NCT05735028
Drug: Centipeda minima+PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
Trial: NCT05735028
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor
Trial: NCT06678399
Drug: KELI-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
Trial: NCT05141786
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT06616077
Drug: Oral Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
Trial: NCT06616077
Drug: Placebo Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa butter
Trial: NCT06662760
Drug: TQB3002 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
Trial: NCT06090890
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Trial: NCT05668455
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drops 4 times a day
Trial: NCT05746143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two days preoperatively and five days postoperatively
Trial: NCT06659549
Drug: GAL-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval